Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
On August 19, pharmaceutical giants Merck and Moderna announced a groundbreaking development in the fight against cancer. The duo unveiled a personalized vaccine specifically designed for patients with melanoma, a type of skin cancer. The results of this study, conducted in collaboration with the Interpath-001 study sponsored by both companies, revealed that patients who received the vaccine lived significantly longer without the cancer returning compared to those who did not receive the treatment.
The announcement sent shockwaves through the medical community and among cancer patients. The innovative approach of tailoring a vaccine to an individual's specific cancer type has the potential to revolutionize cancer treatment and management. However, the success of this personalized therapy hinges on the swift implementation of widespread use.
While the prospect of a vaccine that could extend the lives of melanoma patients without recurrence is undeniably promising, the path ahead is not without challenges. Pricing considerations, including potential local taxes, must be addressed during the checkout process. Additionally, Merck's P.A.O., a member of the scientific advisory committee for the Interpath-001 study, disclosed that he has received research funding from and/or advised various organizations, including Agenus, AstraZeneca/MedImmune, Bristol-Meyers Squibb, Celldex, CytomX, Evaxion, Immunetune, Imunon, LGChem, Moderna, and Neon T.
Written by urgent.news from Nature's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
